UCB S.A. Stock
UCB S.A. shows a slight decrease today, losing -€0.400 (-0.160%) compared to yesterday.
So far the community has only identified positive things for UCB S.A. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of UCB S.A. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of UCB S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| UCB S.A. | -0.160% | -7.888% | -4.509% | 36.222% | 5.265% | 209.359% | 199.138% |
| Bayer AG ADR | -8.410% | -6.667% | -9.259% | 78.182% | 11.364% | -31.944% | -24.615% |
| Novartis AG ADR | -0.350% | 2.143% | 11.284% | 35.545% | 20.675% | 77.861% | 95.890% |
| Teva Pharmaceutical Industries Ltd ADR | 0.700% | 0.347% | -4.305% | 81.761% | 7.435% | 207.447% | 226.185% |
Comments
UCB (OTCMKTS:UCBJF) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Show more
Ratings data for UCBJF provided by MarketBeat
UCB (OTCMKTS:UCBJF) had its "overweight" rating reaffirmed by analysts at Stephens.
Show more
Ratings data for UCBJF provided by MarketBeat
UCB (OTCMKTS:UCBJF) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for UCBJF provided by MarketBeat